In the hunt for novel treatments against TNBC, researchers have identified a new protein inhibitor with a chemotherapy drug. Triple negative breast cancer is the subtype of breast cancer, tends to be more aggressive and caused by the lack of three receptors such as estrogen receptors, progesterone receptors and HER2 (Human epidermal growth factor receptor). Triple negative breast cancer does not express hormone receptor and it occurs in about 15 percent of patients with breast cancer. This type of cancer can be cured by chemotherapy because triple negative breast cancer does not respond to receptor targeted treatments.
Generally Cancer cells treated with the drug combination were less likely to spread in cell culture and were less viable in an animal model. In this present study, the drugs studied were each tested separately in triple-negative breast cancer cell lines and in mice with the Triple negative breast cancer disease. The researchers then executed the treatments in combination with drugs. Combination of the drugs with chemotherapy produced a synergistic effect that was more effective than either drug alone. The cancer cells treated with the drug combination were less likely to multiply or spread in cell culture and were less viable in an animal model. i.e the researchers found that the combination of chemotherapy drug eribulin with a new protein inhibitor is more effective than the either drug alone. i.e. the combination of CYC065 and eribulin had a synergistic effect against the growth and development of triple-negative breast cancer. Compared to previous study, in this study researchers have found that the combination of Cyclin Dependent Kinases inhibitor called CYC065 with chemotherapy drug eribulin, which had shown promise in prior clinical trials for the treatment of triple-negative breast cancer.
New therapeutic targets and treatment strategies are fundamental to improve outcomes for women with this Triple negative breast cancer. Yet, researchers have to find out the study to develop a clinical trial to test the drug combination in patients with triple-negative breast cancer.